The greatest drawback is that a drug to help people with Alzheimers is still not available. The business realities: The stock has less than 2% shares short.Analysts tended to view Bapi success at 20%. No big surprise.The writedown affects book value. It is a non-cash event. Actually, it may enhance cash as spending on Bapi will be reduced. There may be a dip, but this is not a catastrophic event. This company is all about 1 billion in sales per year.
MANY hate eln from the old days and will pummelit in revengeyou see them here again